secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001628280-24-034736
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Q2 revenue $7.8M vs $0.5M YoY; HEPZATO KIT generates $6.6M
------------------------------------------------------------------

- Revenue $7.8M ($6.6M HEPZATO US, $1.2M CHEMOSAT Europe) vs $0.5M prior year.
- Cash and investments $19.9M; final principal payment submitted to Avenue Venture.
- Activated 8 US treating centers; received CMS NTAP status for HEPZATO (Aug 1, 2024).
- Appointed Dr. Bridget Martell to Board; extended melphalan supply agreement to 2028.
- FOCUS study results published in Annals of Surgical Oncology; accepted for ESMO poster.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828024034736/0001628280-24-034736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828024034736/dcth-20240805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-034736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer